For the third year in a row, disputes between landlords and tenants were the most frequent reason for complaints.
Discover the top 3 undervalued Consumer Staples Distribution & Retail stocks for Thursday, February 06 based on AAII’s Stock Grades.
Overkill, and with some concerns Keep the quirky smartphone gadgets coming Smartphone accessories can feel a ... end the days of having to charge your phone, and as wild as it sounds, it actually ...
Swiss IoT module maker u-blox is to phase out its loss-making cellular IoT business, the firm has said. The division has over 200 employees; jobs are expected to go with its closure. It made revenue ...
It looks like T-Mobile is now accepting customers into the free beta program for SpaceX’s cellular Starlink service—but only if you have the latest Samsung handsets. On Tuesday, a number of T ...
The world's biggest gathering of humans is also a much-awaited event for India's consumer businesses. In fact, the Kumbh is the most visible part of a big driver of India's economy, the festival cycle ...
J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders
(AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of central ...
Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...
J&J has offered to buy each share of Intra-Cellular for $132, representing a 39% premium to the stock's closing price on Friday. Shares of Intra-Cellular rose 34% to $128 in afternoon trading ...
Johnson & Johnson (J&J) has announced it will acquire Intra-Cellular Therapies, a company specialising ... as J&J seeks to bolster its portfolio following the spin-off of its consumer health division ...
Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of the ...
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results